CRL vs NAII vs PFE Stock Comparison

Charles River Laboratories International, Natural Alternatives International and Pfizer Prices as of Nov 16, 2026 Peers: Industry group
PFE Pfizer Inc
$28.88 -2.3% 1M +15.2% 1Y
Market cap
$162.19B
P/E
40.2x
Revenue (TTM)
$63.63B
Div. yield
0.06%
Pharmaceuticals Healthcare
8 wins

Head to Head

11 decided of 12

Pfizer leads on 8 of the 12 questions below (Pfizer 8, Charles River Laboratories International 2, Natural Alternatives International 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionCRLNAIIPFELeader
Larger companyMarket capitalisation $15.86B $5.65M $162.19B PFE
Cheaper on earningsLower P/E, profitable companies only 394.8x -0.2x 40.2x PFE
Cheaper on forward earningsLower price / next fiscal year consensus EPS 30.8x — 9.8x PFE
Faster revenue growthRevenue growth, trailing twelve months -1.2% -1.1% +1.3% PFE
More profitableNet margin, trailing twelve months 1.0% -17.2% 6.3% PFE
Better return on capitalReturn on invested capital 0.0% -32.5% 12.3% PFE
Less leveragedLower net debt / EBITDA 5.1x -0.6x 1.9x NAII
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.06% –
Better 1-year returnPrice return, last 12 months +100.0% -69.4% +15.2% CRL
Better 5-year returnAnnualised price return, 5 years -3.1%/yr -41.3%/yr -10.7%/yr CRL
Less volatileAnnualised volatility, 1 year 47.6% 65.7% 21.6% PFE
Higher overall scoreMean of the five percentile scores vs peers 56/100 36/100 62/100 PFE

Percentile Scorecard

CRLNAIIPFE

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisCRLNAIIPFE
Valuation 70 #4 of 11 40 #7 of 11 94 #39 of 659
Growth 20 #9 of 11 0 #11 of 11 35 #399 of 617
Profitability 70 #4 of 11 40 #7 of 11 92 #49 of 593
Financial Health 50 #7 of 13 42 #8 of 13 24 #517 of 680
Shareholder Returns 71 #3 of 8 57 #4 of 8 65 #160 of 459
Overall 56 36 62
  • CRL ranked among 13 companies in Pharma Services
  • NAII ranked among 13 companies in Pharma Services
  • PFE ranked among 693 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodCRLNAIIPFESPY
1 month +11.8%-15.7%-2.3% -3.0%
3 months +17.1%-52.7%+7.5% -4.2%
6 months +123.9%-62.5%+14.0% +0.2%
Year to date +68.3%-72.9%+16.0% +8.5%
1 year +100.0%-69.4%+15.2% +10.1%
3 years +77.5%-84.2%-3.5% +64.1%
3 years, per year +21.1%-46.0%-1.2% +18.0%
5 years -14.6%-93.0%-43.2% +58.1%
5 years, per year -3.1%-41.3%-10.7% +9.6%
10 years +364.3%-92.3%-9.6% +239.6%
10 years, per year +16.6%-22.6%-1.0% +13.0%

Risk

MeasureCRLNAIIPFESPY
Volatility, 1Y 47.6%65.7%21.6% 13.8%
Downside volatility, 1Y 44.7%78.1%21.5% 14.2%
Beta vs S&P 500, 1Y 1.240.930.25 1.00
Return / volatility, 1Y 2.10-1.060.71 0.74
Max drawdown, 5Y -74.6%-93.2%-64.8% -25.4%
From 52-week high -10.7%-79.9%-6.2% -5.0%
52-week high $375.83$4.83$30.79 $779.14
52-week low $149.93$0.95$23.67 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleCRLNAIIPFE
P/E now vs peer median 402.1xmedian 34.7x -0.3xmedian 34.7x 40.8xmedian 17.1x
P/S now vs peer median 4.1xmedian 2.5x 0.0xmedian 2.5x 2.6xmedian 8.3x
EV/EBITDA now vs peer median 41.5xmedian 29.1x -1.0xmedian 29.1x 8.2xmedian 15.1x
P/FCF now vs peer median 40.5xmedian 21.0x -0.9xmedian 21.0x 14.0xmedian 18.1x
P/B now vs peer median 5.0xmedian 1.6x 0.1xmedian 1.6x 1.8xmedian 2.0x
PEG now vs peer median -6.49median 1.98 0.00median 1.98 -1.47median 0.43

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsCRLNAIIPFE
Revenue $3.98B $132.91M $63.63B
Gross profit $1.33B $5.87M $46.69B
Operating income $158.98M -$21.62M $19.40B
Net income $39.65M -$22.88M $4.06B
Free cash flow $399.63M -$6.63M $11.79B
R&D – – $11.52B
EPS (diluted) $0.83 $-3.77 $0.70
Cash & equivalents $200.38M $6.49M $1.82B
Total debt $2.44B $17.03M $62.67B
Shares (diluted) 48.58M 6.07M 5.75B
Enterprise value $15.07B -$24.81M $109.55B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricCRLNAIIPFE
P/E 402.1x -0.3x 40.8x
P/FCF 40.5x -0.9x 14.0x
P/Operating cash flow 26.0x -1.6x 11.6x
P/S 4.1x 0.0x 2.6x
P/B 5.0x 0.1x 1.8x
P/Tangible book 5.4x 0.1x 3.8x
EV/EBITDA 41.5x -1.0x 8.2x
EV/EBIT 115.9x -0.8x 11.0x
EV/Revenue 4.6x 0.1x 3.3x
EV/FCF 46.1x -2.5x 18.1x
EV/Operating cash flow 29.6x -4.5x 15.0x
PEG (3Y EPS CAGR) -6.49 0.00 -1.47

Growth

14 metrics
MetricCRLNAIIPFE
Revenue growth (1Y) -1.2% -1.1% 1.3%
Revenue CAGR (3Y) -1.9% -2.8% -3.2%
Gross profit growth (1Y) 2.1% -48.7% 0.0%
Gross profit CAGR (3Y) -4.8% -28.3% 2.7%
Operating income growth (1Y) 12.8% -230.6% -14.8%
Operating income CAGR (3Y) -37.4% -117.1% 7.4%
Net income growth (1Y) 149.8% -92.6% -58.9%
Net income CAGR (3Y) -56.5% -216.0% -27.2%
EPS growth (1Y) 149.0% -90.4% -59.2%
EPS CAGR (3Y) -61.9% -212.3% -27.7%
Operating cash flow growth (1Y) -17.0% -169.1% 8.4%
Operating cash flow CAGR (3Y) -3.7% -30.6% 5.6%
Free cash flow growth (1Y) -26.5% -757.3% 13.6%
Free cash flow CAGR (3Y) 2.7% -39.8% 13.0%

Profitability

14 metrics
MetricCRLNAIIPFE
Gross margin 33.3% 4.4% 73.4%
EBITDA margin 11.2% -12.8% 40.7%
Operating margin 4.0% -16.3% 30.5%
Pretax margin -2.5% -17.2% 6.7%
Net margin 1.0% -17.2% 6.3%
FCF margin 10.0% -5.0% 18.5%
Operating cash flow margin 15.7% -2.8% 22.3%
Return on equity 1.4% -45.8% 4.7%
Return on assets 0.6% -18.5% 2.0%
Return on invested capital 0.0% -32.5% 12.3%
Return on capital employed 2.5% -26.7% 11.3%
Asset turnover 0.5x 1.1x 0.3x
Cash conversion (OCF / net income) 15.7x 0.2x 3.5x
Stock comp / revenue 2.0% 0.4% 1.7%

Financial Health

11 metrics
MetricCRLNAIIPFE
Debt / assets 32.8% 14.9% 30.6%
Debt / equity 0.8x 0.4x 0.7x
Net debt / EBITDA 5.1x -0.6x 1.9x
Debt / FCF 6.1x -2.6x 5.3x
Liabilities / assets 56.6% 58.8% 56.4%
Equity / assets 43.4% 41.2% 43.6%
Interest coverage 1.5x – –
Current ratio 1.4x 1.4x 1.4x
Quick ratio 0.9x 0.5x 0.9x
Cash ratio 0.2x 0.2x 0.4x
Altman Z-score 3.30 1.19 2.34

Shareholder Returns

7 metrics
MetricCRLNAIIPFE
Dividend yield – – 6.0%
Net buyback yield 1.8% 1.4% –
Shareholder yield 1.8% 1.4% 6.0%
Payout ratio (earnings) – – 241.2%
Payout ratio (FCF) – – 83.1%
Dividend growth (1Y) – – 0.9%
Dividend CAGR (3Y) – – 2.2%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusCRLNAIIPFE
Forward P/E 30.8xFY2026 – 9.8xFY2026
EPS, next fiscal year $10.99FY2026 – $2.95FY2026
EPS growth, next FY +6.9%FY2026 – -8.4%FY2026
EPS growth, the year after +20.7% – -5.8%
Revenue, next fiscal year $3.85BFY2026 – $61.46BFY2026
Revenue growth, next FY -4.2%FY2026 – -1.8%FY2026
Revenue growth, the year after +1.2% – +4.0%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersCRLNAIIPFE
Held by institutions 100.0% 10.5% 66.9%
Institutions holding 571 24 2,842
Change in shares held, QoQ -0.7% +6.0% +2.0%
Institutions buying 271 8 1,327
Institutions selling 204 7 1,206
Buyers to sellers 1.33 1.14 1.10

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

CRLNAIIPFE
CRL 1.00 0.12 0.15
NAII 0.12 1.00 0.08
PFE 0.15 0.08 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, CRL, NAII and PFE?

Pfizer (PFE) is the largest by market capitalisation: Charles River Laboratories International (CRL) $15.86B, Natural Alternatives International (NAII) $5.65M, Pfizer (PFE) $162.19B.

Which stock is cheaper, CRL, NAII and PFE?

Pfizer (PFE) trades on the lowest price-to-earnings ratio (Charles River Laboratories International (CRL) 394.8x, Natural Alternatives International (NAII) -0.2x, Pfizer (PFE) 40.2x). On next year's consensus earnings, Pfizer (PFE) is cheapest (Charles River Laboratories International (CRL) 30.8x, Pfizer (PFE) 9.8x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Pfizer (PFE) grew revenue fastest over the trailing twelve months: Charles River Laboratories International (CRL) -1.2%, Natural Alternatives International (NAII) -1.1%, Pfizer (PFE) +1.3%.

Which company is more profitable?

Pfizer (PFE) has the highest net margin (Charles River Laboratories International (CRL) 1.0%, Natural Alternatives International (NAII) -17.2%, Pfizer (PFE) 6.3%). On return on invested capital, Pfizer (PFE) leads (Charles River Laboratories International (CRL) 0.0%, Natural Alternatives International (NAII) -32.5%, Pfizer (PFE) 12.3%).

Which stock has performed better?

Over the past year Charles River Laboratories International (CRL) returned the most: Charles River Laboratories International (CRL) +100.0%, Natural Alternatives International (NAII) -69.4%, Pfizer (PFE) +15.2%. Over five years, Charles River Laboratories International (CRL) compounded fastest (Charles River Laboratories International (CRL) -3.1%/yr, Natural Alternatives International (NAII) -41.3%/yr, Pfizer (PFE) -10.7%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Charles River Laboratories International (CRL) 0.00%, Natural Alternatives International (NAII) 0.00%, Pfizer (PFE) 0.06%. Charles River Laboratories International (CRL) and Natural Alternatives International (NAII) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Pfizer (PFE) has been the steadiest (Charles River Laboratories International (CRL) 47.6%, Natural Alternatives International (NAII) 65.7%, Pfizer (PFE) 21.6%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, CRL, NAII and PFE?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Pfizer (PFE) leads on 8. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.